Eculizumab use while Breastfeeding
Drugs containing Eculizumab: Soliris
Eculizumab Levels and Effects while Breastfeeding
Summary of Use during Lactation
Information from one patient indicates that a maternal dose of eculizumab of 900 mg every 12 days produced undetectable levels in breastmilk. If eculizumab is required by the mother, it is not a reason to discontinue breastfeeding. However, until more data are available, eculizumab should only be used with careful monitoring during breastfeeding.
Drug Levels
Maternal Levels. One woman with paroxysmal nocturnal hemoglobinuria had received eculizumab for 5 years before becoming pregnant. She continued to receive the drug during pregnancy at a dosage of 900 mg every 12 days and postpartum. At delivery, she had a therapeutic eculizumab serum concentration of 116.1 mg/L. Breastmilk samples taken on days 1, 2, 3, 9 and 10 after delivery contained no detectable drug (lower limit of assay and time of last dose not stated).[1][2]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Possible Effects on Lactation
Relevant published information was not found as of the revision date.
References
1. Kelly R, Arnold LM, Richards SJ, Hill A, Bomken C, Hanley J et al. Successful pregnancy outcome in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Haematologica. 2009;94 (Suppl. 2):452. Abstract.
2. Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149:446-50. PMID: 20151973
Eculizumab Identification
Substance Name
CAS Registry Number
219685-50-4
Drug Class
- Antibodies, Monoclonal, Humanized
Administrative Information
LactMed Record Number
999
Information from the National Library of Medicine's LactMed Database.
Last Revision Date
2012-08-14
Disclaimer
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
See Also...
- Eculizumab use during Pregnancy
- Eculizumab Consumer Information
- Breastfeeding Support Group
- Safe Medications during Breastfeeding
- Medicine use while Breastfeeding
- Medicine use during Pregnancy
Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.
